OBJECTIVES: The aim of this study was to evaluate the frequency, characteristics and risk factors of lipid changes associated with lopinavir/ritonavir treatment in antiretroviral-naive patients. METHODS: A prospective cohort of 107 antiretroviral-naive HIV-infected patients was followed for 12 months after starting lopinavir/ritonavir-based highly active antiretroviral therapy. RESULTS: At 12 months, percentages of patients with hypercholesterolaemia and hypertriglyceridaemia were 17.4% and 40%, respectively. Mean increases in total cholesterol and triglycerides were 40.7 and 73.3 mg/dL. There was a significant increase in both low-density and high-density (HDL) cholesterol, and no increase in the total cholesterol/HDL ratio (from 4.16 at baseline to 4.49 after 12 months). Baseline cholesterol > 200 mg/dL and triglycerides > 150 mg/dL were independent risk factors for dyslipidaemia, while hepatitis C coinfection appeared to be protective. CONCLUSIONS: Patients with elevated lipid values at baseline have the greatest risk of developing hypercholesterolaemia and hypertriglyceridaemia after starting lopinavir/ritonavir. Antiretroviral-naive patients coinfected with hepatitis C have a low risk of developing hyperlipidaemia after starting lopinavir/ritonavir.
OBJECTIVES: The aim of this study was to evaluate the frequency, characteristics and risk factors of lipid changes associated with lopinavir/ritonavir treatment in antiretroviral-naive patients. METHODS: A prospective cohort of 107 antiretroviral-naive HIV-infectedpatients was followed for 12 months after starting lopinavir/ritonavir-based highly active antiretroviral therapy. RESULTS: At 12 months, percentages of patients with hypercholesterolaemia and hypertriglyceridaemia were 17.4% and 40%, respectively. Mean increases in total cholesterol and triglycerides were 40.7 and 73.3 mg/dL. There was a significant increase in both low-density and high-density (HDL) cholesterol, and no increase in the total cholesterol/HDL ratio (from 4.16 at baseline to 4.49 after 12 months). Baseline cholesterol > 200 mg/dL and triglycerides > 150 mg/dL were independent risk factors for dyslipidaemia, while hepatitis C coinfection appeared to be protective. CONCLUSIONS:Patients with elevated lipid values at baseline have the greatest risk of developing hypercholesterolaemia and hypertriglyceridaemia after starting lopinavir/ritonavir. Antiretroviral-naive patients coinfected with hepatitis C have a low risk of developing hyperlipidaemia after starting lopinavir/ritonavir.
Authors: Mitch M Matoga; Mina C Hosseinipour; Evgenia Aga; Heather J Ribaudo; Nagalingeswaran Kumarasamy; John Bartlett; Michael D Hughes Journal: Antivir Ther Date: 2016-10-14
Authors: Josephine H Li; Xiang Qian Lao; Hans L Tillmann; Jennifer Rowell; Keyur Patel; Alexander Thompson; Sunil Suchindran; Andrew J Muir; John R Guyton; Stephen D Gardner; John G McHutchison; Jeanette J McCarthy Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: Phumla Z Sinxadi; Joel A Dave; David C Samuels; Jeannine M Heckmann; Gary Maartens; Naomi S Levitt; C William Wester; David W Haas; Todd Hulgan Journal: AIDS Res Hum Retroviruses Date: 2013-03-15 Impact factor: 2.205
Authors: María Jose Míguez; John E Lewis; Vaughn E Bryant; Rhonda Rosenberg; Ximena Burbano; Joel Fishman; Deshratn Asthana; Rui Duan; Nair Madhavan; Robert M Malow Journal: J Int AIDS Soc Date: 2010-07-13 Impact factor: 5.396